Abstract
The objective of this study was to report the long-term remission results from the ConstaTRE relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (RLAI) or oral quetiapine, dosed according to package-insert recommendations. In the ConstaTRE trial, efficacy and tolerability were recorded for up to 24 months. This post hoc analysis presents remission data, defined, according to the Schizophrenia Working Group criteria, as achieving and maintaining eight core symptoms of schizophrenia that are mild or less over 6 months. Additional secondary outcome measures are also presented. A total of 710 patients were randomized to RLAI (n = 355) or quetiapine (n = 355). Mean mode ± standard deviation (SD) drug doses were RLAI 33 ± 10 mg every 2 weeks and quetiapine 413 ± 159 mg daily. Full remission was achieved by 51.1% of patients with RLAI and 39.3% with quetiapine (p = 0.003). Mean ± SD of full remission durations were not significantly different with RLAI (540 ± 181 days) and quetiapine (508 ± 188 days). Overall tolerability was similar between treatment groups. Among stable patients with schizophrenia or schizoaffective disorder, remission was more likely after switching to RLAI than quetiapine.
| Original language | English |
|---|---|
| Pages (from-to) | 191-199 |
| Number of pages | 9 |
| Journal | Therapeutic Advances in Psychopharmacology |
| Volume | 3 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- antipsychotics
- long-acting injectable risperidone
- quetiapine
- remission
- schizophrenia
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Psychology (miscellaneous)
Cite this
Long-term remission in schizophrenia and schizoaffective disorder : Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). / Smeraldi, Enrico; Cavallaro, Roberto; Folnegović-Šmalc, Vera; Bidzan, Leszek; Emin Ceylan, Mehmet; Schreiner, Andreas.
In: Therapeutic Advances in Psychopharmacology, Vol. 3, No. 4, 2013, p. 191-199.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long-term remission in schizophrenia and schizoaffective disorder
T2 - Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
AU - Smeraldi, Enrico
AU - Cavallaro, Roberto
AU - Folnegović-Šmalc, Vera
AU - Bidzan, Leszek
AU - Emin Ceylan, Mehmet
AU - Schreiner, Andreas
PY - 2013
Y1 - 2013
N2 - The objective of this study was to report the long-term remission results from the ConstaTRE relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (RLAI) or oral quetiapine, dosed according to package-insert recommendations. In the ConstaTRE trial, efficacy and tolerability were recorded for up to 24 months. This post hoc analysis presents remission data, defined, according to the Schizophrenia Working Group criteria, as achieving and maintaining eight core symptoms of schizophrenia that are mild or less over 6 months. Additional secondary outcome measures are also presented. A total of 710 patients were randomized to RLAI (n = 355) or quetiapine (n = 355). Mean mode ± standard deviation (SD) drug doses were RLAI 33 ± 10 mg every 2 weeks and quetiapine 413 ± 159 mg daily. Full remission was achieved by 51.1% of patients with RLAI and 39.3% with quetiapine (p = 0.003). Mean ± SD of full remission durations were not significantly different with RLAI (540 ± 181 days) and quetiapine (508 ± 188 days). Overall tolerability was similar between treatment groups. Among stable patients with schizophrenia or schizoaffective disorder, remission was more likely after switching to RLAI than quetiapine.
AB - The objective of this study was to report the long-term remission results from the ConstaTRE relapse prevention trial, in which clinically stable adults with schizophrenia or schizoaffective disorder treated with oral risperidone, olanzapine, or oral conventional antipsychotics were randomized to risperidone long-acting injectable (RLAI) or oral quetiapine, dosed according to package-insert recommendations. In the ConstaTRE trial, efficacy and tolerability were recorded for up to 24 months. This post hoc analysis presents remission data, defined, according to the Schizophrenia Working Group criteria, as achieving and maintaining eight core symptoms of schizophrenia that are mild or less over 6 months. Additional secondary outcome measures are also presented. A total of 710 patients were randomized to RLAI (n = 355) or quetiapine (n = 355). Mean mode ± standard deviation (SD) drug doses were RLAI 33 ± 10 mg every 2 weeks and quetiapine 413 ± 159 mg daily. Full remission was achieved by 51.1% of patients with RLAI and 39.3% with quetiapine (p = 0.003). Mean ± SD of full remission durations were not significantly different with RLAI (540 ± 181 days) and quetiapine (508 ± 188 days). Overall tolerability was similar between treatment groups. Among stable patients with schizophrenia or schizoaffective disorder, remission was more likely after switching to RLAI than quetiapine.
KW - antipsychotics
KW - long-acting injectable risperidone
KW - quetiapine
KW - remission
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84997901782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84997901782&partnerID=8YFLogxK
U2 - 10.1177/2045125313479127
DO - 10.1177/2045125313479127
M3 - Article
AN - SCOPUS:84997901782
VL - 3
SP - 191
EP - 199
JO - Therapeutic Advances in Psychopharmacology
JF - Therapeutic Advances in Psychopharmacology
SN - 2045-1253
IS - 4
ER -